Research Funds Bonanza Going Up in Smoke?

T he Senate's snuffing of anti-tobacco legislation last month also extinguished some optimism for increased science funding for fiscal year 1999, which begins Oct. 1, 1998. "It's definitely a setback," Mary Woolley, president of Research!America, admits. President Bill Clinton had earmarked some of the anticipated revenue from proposed increases in cigarette taxes to pay for a boost in biomedical research funding. Without that revenue, Research!America's goal of doubling biomedical research fu

Written byPaul Smaglik
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

T he Senate's snuffing of anti-tobacco legislation last month also extinguished some optimism for increased science funding for fiscal year 1999, which begins Oct. 1, 1998.

"It's definitely a setback," Mary Woolley, president of Research!America, admits. President Bill Clinton had earmarked some of the anticipated revenue from proposed increases in cigarette taxes to pay for a boost in biomedical research funding. Without that revenue, Research!America's goal of doubling biomedical research funding in five years becomes more difficult (P. Smaglik, The Scientist, 11[22]:1, Nov. 10, 1997). Even with higher cigarette taxes, that goal would have been challenging. Doubling research requires a 15 percent boost in the National Institutes of Health's budget from FY 1999 to FY 2003; President Clinton has requested an 8.4 percent increase for NIH in FY 1999--a figure that includes projected revenue from tobacco.

Some Republicans had been critical of the budgeting that anticipated cigarette revenue for research. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies